Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Use of the Progressive Return to Activity Guidelines May Expedite Symptom Resolution After Concussion for Active Duty Military.

Bailie JM, Remigio-Baker RA, Cole WR, McCulloch KL, Ettenhofer ML, West T, Ahrens A, Sargent P, Cecchini A, Malik S, Mullins L, Stuessi K, Qashu FM, Gregory E.

Am J Sports Med. 2019 Dec;47(14):3505-3513. doi: 10.1177/0363546519883259. Epub 2019 Nov 13.

PMID:
31718246
2.

Activity Level and Type During Post-acute Stages of Concussion May Play an Important Role in Improving Symptoms Among an Active Duty Military Population.

Remigio-Baker RA, Bailie JM, Gregory E, Cole WR, McCulloch KL, Cecchini A, Stuessi K, Andrews TR, Qashu F, Mullins L, Sargent P, Ettenhofer ML.

Front Neurol. 2019 Jun 19;10:602. doi: 10.3389/fneur.2019.00602. eCollection 2019.

3.

A Comparison of Four Computerized Neurocognitive Assessment Tools to a Traditional Neuropsychological Test Battery in Service Members with and without Mild Traumatic Brain Injury.

Cole WR, Arrieux JP, Ivins BJ, Schwab KA, Qashu FM.

Arch Clin Neuropsychol. 2018 Feb 1;33(1):102-119. doi: 10.1093/arclin/acx036.

PMID:
28444123
4.

Use of a multi-level mixed methods approach to study the effectiveness of a primary care progressive return to activity protocol after acute mild traumatic brain injury/concussion in the military.

Gregory E, West TA, Cole WR, Bailie JM, McCulloch KL, Ettenhofer ML, Cecchini A, Qashu FM.

Contemp Clin Trials. 2017 Jan;52:95-100. doi: 10.1016/j.cct.2016.11.005. Epub 2016 Nov 9.

PMID:
27836507
5.

Profile Analysis of the Neurobehavioral and Psychiatric Symptoms Following Combat-Related Mild Traumatic Brain Injury: Identification of Subtypes.

Bailie JM, Kennedy JE, French LM, Marshall K, Prokhorenko O, Asmussen S, Reid MW, Qashu F, Brickell TA, Lange RT.

J Head Trauma Rehabil. 2016 Jan-Feb;31(1):2-12. doi: 10.1097/HTR.0000000000000142.

PMID:
26716696
6.

Test-retest reliability of four computerized neurocognitive assessment tools in an active duty military population.

Cole WR, Arrieux JP, Schwab K, Ivins BJ, Qashu FM, Lewis SC.

Arch Clin Neuropsychol. 2013 Nov;28(7):732-42. doi: 10.1093/arclin/act040. Epub 2013 Jul 2.

PMID:
23819991
7.

Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, Green CE, Swezey R, Yang C, Qashu F, Braga MF.

J Pharmacol Exp Ther. 2013 Jan;344(1):133-40. doi: 10.1124/jpet.112.198689. Epub 2012 Oct 5.

8.

Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.

Figueiredo TH, Aroniadou-Anderjaska V, Qashu F, Apland JP, Pidoplichko V, Stevens D, Ferrara TM, Braga MF.

Br J Pharmacol. 2011 Nov;164(5):1495-505. doi: 10.1111/j.1476-5381.2011.01427.x.

9.

RDX binds to the GABA(A) receptor-convulsant site and blocks GABA(A) receptor-mediated currents in the amygdala: a mechanism for RDX-induced seizures.

Williams LR, Aroniadou-Anderjaska V, Qashu F, Finne H, Pidoplichko V, Bannon DI, Braga MF.

Environ Health Perspect. 2011 Mar;119(3):357-63. doi: 10.1289/ehp.1002588. Erratum in: Environ Health Perspect. 2013 May;121(5):A146.

10.

The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.

Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF.

J Pharmacol Exp Ther. 2011 Feb;336(2):303-12. doi: 10.1124/jpet.110.171835. Epub 2010 Oct 20.

11.

Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology.

Apland JP, Figueiredo TH, Qashu F, Aroniadou-Anderjaska V, Souza AP, Braga MF.

Neurotoxicology. 2010 Sep;31(5):485-92. doi: 10.1016/j.neuro.2010.05.014. Epub 2010 Jun 8.

12.

Primary brain targets of nerve agents: the role of the amygdala in comparison to the hippocampus.

Aroniadou-Anderjaska V, Figueiredo TH, Apland JP, Qashu F, Braga MF.

Neurotoxicology. 2009 Sep;30(5):772-6. doi: 10.1016/j.neuro.2009.06.011. Epub 2009 Jul 8.

13.

Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis.

Fritsch B, Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Rogawski MA, Braga MF.

Neuroscience. 2009 Sep 29;163(1):415-29. doi: 10.1016/j.neuroscience.2009.06.034. Epub 2009 Jun 18.

14.

Diazepam administration after prolonged status epilepticus reduces neurodegeneration in the amygdala but not in the hippocampus during epileptogenesis.

Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Apland JP, Braga MF.

Amino Acids. 2010 Jan;38(1):189-97. doi: 10.1007/s00726-008-0227-2. Epub 2009 Jan 7.

15.

Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy.

Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF.

Epilepsy Res. 2008 Feb;78(2-3):102-16. doi: 10.1016/j.eplepsyres.2007.11.011. Epub 2008 Jan 15. Review.

16.

Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders.

Aroniadou-Anderjaska V, Qashu F, Braga MF.

Amino Acids. 2007;32(3):305-15. Epub 2006 Oct 18. Review.

PMID:
17048126

Supplemental Content

Support Center